CHA University
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.cha.ac.kr
Clinical Trials
70
Active:2
Completed:22
Trial Phases
5 Phases
Phase 1:3
Phase 2:2
Phase 3:9
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials
Not Applicable
37 (63.8%)Phase 3
9 (15.5%)Phase 4
7 (12.1%)Phase 1
3 (5.2%)Phase 2
2 (3.4%)Carbohydrate Mouth Rinsing and Cognitive Response During Exercise
Not Applicable
Completed
- Conditions
- Exercise Performance of Fit Athletes
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- CHA University
- Target Recruit Count
- 11
- Registration Number
- NCT07099807
- Locations
- 🇰🇷
CHA University, Human Performance Lab, Seongnam-si, Gyeonggi-do, Korea, Republic of
The Rule-Out Acute Myocardial Infarction Using Aritifical Intelligence Electrocardiogram (ROMIAE) 2 Trial
Not Applicable
Not yet recruiting
- Conditions
- Myocardial Infarction (MI)Chest Pain Rule Out Myocardial Infarction
- First Posted Date
- 2025-06-19
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- CHA University
- Target Recruit Count
- 4670
- Registration Number
- NCT07027891
Medipixel XA-Assisted PCI in Coronary Artery Disease
Not Applicable
Recruiting
- Conditions
- Percutaneous Coronary Intervention (PCI)Coronary Arterial Disease (CAD)
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- CHA University
- Target Recruit Count
- 830
- Registration Number
- NCT06985693
- Locations
- 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer (GemCiNT)
Recruiting
- Conditions
- Locally Advanced Biliary Tract CancersMetastatic Biliary Tract Cancers
- Interventions
- Drug: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab.
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- CHA University
- Target Recruit Count
- 61
- Registration Number
- NCT06893380
- Locations
- 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
The Analysis of Efficacy Factors for Autologous Platelet-Rich Plasma Therapy in the Treatment of Elbow Tendinopathy
Phase 4
Not yet recruiting
- Conditions
- Elbow Tendinopathy
- Interventions
- Biological: Autologous Platelet-Rich Plasma (PRP) Injection
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- CHA University
- Target Recruit Count
- 30
- Registration Number
- NCT06815042
- Locations
- 🇰🇷
Bundang CHA Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found